Rock Springs Capital Management LP Chinook Therapeutics, Inc. Transaction History

Rock Springs Capital Management LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$18.66 - $38.58 $2.08 Million - $4.29 Million	-111,232 Reduced 21.92%	396,280 $15.2 Million
Q2 2022 Aug 15, 2022	SELL	$12.59 - $18.8 $2.43 Million - $3.63 Million	-192,837 Reduced 27.53%	507,512 $8.88 Million
Q1 2022 May 16, 2022	SELL	$12.02 - $16.69 $240,400 - $333,800	-20,000 Reduced 2.78%	700,349 $11.5 Million
Q4 2021 Feb 14, 2022	BUY	$10.69 - $16.83 $344,218 - $541,926	32,200 Added 4.68%	720,349 $11.7 Million
Q3 2021 Nov 15, 2021	BUY	$11.5 - $14.86 $65,550 - $84,702	5,700 Added 0.84%	688,149 $8.78 Million
Q2 2021 Aug 16, 2021	BUY	$13.6 - $18.98 $127,840 - $178,412	9,400 Added 1.4%	682,449 $9.64 Million
Q1 2021 May 17, 2021	BUY	$14.17 - $19.11 $59,514 - $80,262	4,200 Added 0.63%	673,049 $10.5 Million
Q4 2020 Feb 16, 2021	BUY	$11.9 - $20.91 $7.96 Million - $14 Million	668,849 New	668,849 $10.6 Million

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Rock Springs Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Rock Springs Capital Management LP with notifications on news.